HeartBeam Reports Fourth Quarter and Full Year 2025 Results

HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment. First Commercial Partner ClearCardi ...

HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio (TM), a leading preventive ...

HeartBeam (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New ...
TMCnet

HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Management will host a presentation ...
News Medical on MSN

AI-powered wearable ECG system detects myocardial ischemia minutes earlier

Myocardial ischemia, the primary driver of heart attacks, remains the leading cause of death and disability worldwide. Delays in diagnosis directly correlate with increased myocardial necrosis, higher ...
TMCnet

HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at ...
Becker's Hospital Review

1st synthesized 12-lead ECG to launch in 2026

HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
MassDevice

HeartBeam, Mount Sinai ink strategic AI collab to bring heart monitoring into the home

HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.
Nasdaq

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
Business Wire

HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
Nasdaq

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...